Recent Updates
Recently added Catalysts
BAX Positive Sentiment

Baxter Launches HEMOPATCH Sealing Hemostat in New Zealand, a Room-Temperature Collagen Pad Approved for Hemostasis and Sealing Over the past two decades, surgical techniques have increasingly shifted toward minimally invasive approaches, requiring adapted workflows and...

Key Takeaway: Baxter has launched the Hemopatch Sealing Hemostat in New Zealand, following its global introduction in Europe. This room-temperature collagen pad is designed for hemostasis and sealing in both open and minimally invasive surgeries. Clinical visits led by Professor Ulrich Stock highlighted its potential to improve patient outcomes by reducing blood loss and enhancing recovery times.
Price reaction · baseline $23.99 (2025-09-12 close) · clean, no other BAX news in the window
day 0 close · peak
-0.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Introduction of a new hemostatic product in New Zealand.
  • Designed for both open and minimally invasive surgical procedures.
  • Focus on reducing blood loss and improving patient recovery.
  • Supported by clinical insights from experienced surgeons.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+18%
120-day peak, hindsight
Typical move
1.9%
average across 12 past catalysts
Lead asset
Dianeal
Phase 3 · End Stage Renal Disease (ESRD)

Full Press Release Details

DEERFIELD, Ill. , Sept. 15, 2025 /PRNewswire/ -- Over the past two decades, surgical techniques have increasingly shifted toward minimally invasive approaches, requiring adapted workflows and skillsets. At the same time, patient complexity has grown, calling for tailored strategies to support safe and effective care in the operating room.
After its global launch in Europe , Baxter has introduced Hemopatch Sealing Hemostat in New Zealand . Hemopatch Sealing Hemostat is a room-temperature storage collagen pad designed for hemostasis and sealing in both open and minimally invasive surgical procedures (MIS).
To support its introduction, a series of clinical visits took place across several hospitals. Professor Ulrich Stock , Head of Cardiothoracic and Transplant Surgery at Fiona Stanley Hospital ( Perth, Australia ) led the sessions, presented his insights from daily clinical practice. Reflecting on the product's development and its role in today's surgical environment, he shared:
"I believe it's very important for the industry to listen to their surgeons—to recognize when something is good or fair but could be improved. It takes time and testing, but ultimately it benefits everyone: the surgeon, the patient, and the wider medical community.
We've learned that when we reduce blood loss and avoid transfusions, patients recover faster and often do better in the long term. That's especially important as we see more patients with complex histories. In heart transplantation, for example, 60% of our patients have had previous surgeries. These changes in patient profiles demand new tools and better support in the OR."
The roadshow provided a valuable opportunity for surgical teams to explore the updated features—focused on ease of use and supporting positive patient outcomes.
We look forward to sharing further updates as the global rollout expands.
For more information on Hemopatch sealing hemostat, Visit: https://advancedsurgery.baxter.eu/hemopatch
Reference:
• Hemopatch sealing hemostat Instructions for Use.
Manufacturer:
Baxter Healthcare SA
Thurgauerstrasse 130 Glattbrugg,
ZÜRICH, 8152 Switzerland
Class of Device: III
CE 0123
This content is intended solely for healthcare professionals and should not be interpreted as medical advice. Please consult with a qualified healthcare provider for any health concerns.
Hemopatch sealing hemostat is approved for use only in selected countries. For specific information on the availability and regulatory status of Hemopatch sealing hemostat room temperature in your country, we recommend contacting your local Baxter Healthcare sales representative.
Baxter and Hemopatch are trademarks of Baxter International Inc. or its subsidiaries.

Frequently Asked Questions

What is the Hemopatch Sealing Hemostat?

The Hemopatch Sealing Hemostat is a room-temperature collagen pad designed for hemostasis and sealing in surgical procedures.

Where has Baxter launched the Hemopatch?

Baxter has launched the Hemopatch Sealing Hemostat in New Zealand.

Who led the clinical visits for Hemopatch?

Professor Ulrich Stock led the clinical visits across several hospitals.

What are the benefits of using Hemopatch?

Hemopatch aims to reduce blood loss and improve patient recovery times during surgeries.

Last updated: Sep 15, 2025